AMS_COVID.pdf (308.97 kB)

When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19.

Download (308.97 kB)
journal contribution
posted on 04.02.2021, 12:04 by Talal Almas, Salman Hussain, Abdul Haadi, Maryam Ehtesham, Afnan Hassan, Abdul Wali Khan, Aamir Hameed

The coronavirus disease 2019 (COVID-19) continues to wreak havoc, culminating in soaring morbidity and mortality worldwide. To date, a plethora of pharmaceutical regimens has been employed in the treatment of the infection, but management of the ailment still remains largely supportive. In addition to antivirals such as remdesivir, azithromycin and tocilizumab also remain the cornerstone of current therapeutic management. Recent research has divulged that the exorbitantly high fatality and morbidity rates associated with COVID-19 can be attributed, in part, to an aberrant and dysregulated immune response that ensues secondary to the cytokine storm observed in COVID-19 [1]. Corticosteroids have traditionally remained exceedingly imperative in the management of hyperinflammatory states. Owing to their potent anti-inflammatory properties, corticosteroids have remained at the epicentre of a therapeutic conundrum surrounding the optimal management of COVID-19.


History

Comments

The original article is available at https://www.sciencedirect.com

Published Citation

Almas T, Hussain S, Haadi A, Ehtesham M, Hassan A, Khan AW, Hameed A. When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19. Annals of Medicine and Surgery. 2021;(62):236-238.

Publication Date

21 January 2021

Department/Unit

  • Anatomy and Regenerative Medicine
  • RCSI Tissue Engineering Group (TERG)
  • Undergraduate Research

Research Area

  • Surgical Science and Practice
  • Biomaterials and Regenerative Medicine

Publisher

Elsevier BV

Version

  • Published Version (Version of Record)

Licence

Exports

Royal College of Surgeons in Ireland

Licence

Exports